Browsing by Author Gibbs, Peter

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 23  next >
Issue DateTitleAuthor(s)Citation
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2018Adjuvant therapy for resected colon cancer 2017, including the IDEA analysisPavlakis, Nick; Tang, Monica; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos (Chris); Peeters, Marc; Price, Timothy; Roy, Amitesh; Segelov, Eva; Shapiro, Jeremy; Tebbutt, Niall; Northern Clinical School: Medicine; NH&MRC Clinical Trials CentreAdjuvant therapy for resected colon cancer 2017, including the IDEA analysis, Expert Review of Anticancer Therapy, vol.18, 4, 2018,pp 339-349
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Pavlakis, Nick; Simes, Robert John; Blondal, J; Burkes, R L; Gibbs, Peter; Jonker, D; Karapetis, Christos; Lee, U; Meharchand, J; Moore, Malcolm; O'Callaghan, Chris; Price, T.J.; Rubin, S; Shapiro, Jeremy; Tebbutt, Niall C; Tu, Dongsheng; van Hazel, Guy; Vickers, M; Zalcberg, John; Zhu, L; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreAssociation of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17, Annals of Oncology, vol.24, 4, 2013,pp 953-960
2004Audit Of Postoperative Chemoradiotherapy As Adjuvant Therapy For Resected Gastroesophageal Adenocarcinoma: An Australian Multicentre Experience.Yip, Desmond; Burmeister, Bryan; Carroll, Susan; Chao, Michael W.; Gibbs, Peter; Goldstein, David; Hughes, Brett G; Karapetis, Christos (Chris); MedicineAudit Of Postoperative Chemoradiotherapy As Adjuvant Therapy For Resected Gastroesophageal Adenocarcinoma: An Australian Multicentre Experience., ANZ Journal of Surgery, vol.74,(11),2004,pp 951-956
2013An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]Clarke, Stephen; Burge, Matt; Cordwell, Cassandra; Gibbs, Peter; Reece, William; Tebbutt, Niall; Concord Clinical School: MedicineAn Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT], BMC Cancer, vol.13, N/A, 2013,pp 1-7
2010Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive carePavlakis, Nick; Asmis, T; Dueck, D; Gibbs, Peter; Jeffery, M; Jonker, D; Karapetis, Christos; Langer, Christine; O’Callaghan, C; Powell, E; Tu, D.; Whittom, R; Zhu, L; Northern Clinical School: MedicineComorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care, Annals of Oncology, vol.22, 1,pp 118-126
2015Comparison of ECOG/WHO Performance Status and ASA Score as a Measure of Functional StatusBadgery-Parker, Tim; Dobbins, Timothy; Jorgensen, Mikaela Louise; Young, Jane; Currow, David; Faragher, Ian; Gibbs, Peter; Jones, Ian T.; Northern Clinical School: Kolling Institute; School of Public Health: Public Health; School of Public Health: Medicine; School of Public Health: Public HealthComparison of ECOG/WHO Performance Status and ASA Score as a Measure of Functional Status, Journal of Pain and Symptom Management, vol.49, 2, 2015,pp 258-264
2014Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Pavlakis, Nick; Arnold, Dirk; Burge, Matthew; Gibbs, Peter; Haller, Daniel; Karapetis, Christos; Price, Timothy; Punt, Cornelis JA; Segelov, Eva; Shapiro, J; Tebbutt, Niall; Northern Clinical School: MedicineCurrent opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013, Expert Review of Anticancer Therapy, vol.14, 12, 2014,pp 1477-1493
2004Evidence Supports Adjuvant Radiotherapy In Selected Patients With Rectal Cancer.Yip, Desmond; Chao, Michael W.; Gibbs, Peter; Jones, Ian T.; MedicineEvidence Supports Adjuvant Radiotherapy In Selected Patients With Rectal Cancer., ANZ Journal of Surgery 2005, vol.74,(3),2004,pp 152-157
2017First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsGebski, Val; et al, Various; Findlay, Michael; Gibbs, Peter; Heinemann, Volker; Peeters, Marc; Ricke, Jens; Sharma, Navesh K; Taieb, Julien; Wasan, Harpreet; Weaver, Andrew; NH&MRC Clinical Trials CentreFirst-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials, The Lancet Oncology, vol.18, 9, 2017,pp 1159-1171
2015Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumabGebski, Val; Price, Timothy; Sjoquist, Katrin; et al, Various; Field, Kathryn; Gibbs, Peter; McKendrick, J; Nott, Louise M; Roohullah, Aflah; Shapiro, Jeremy; Tran, Ben; Wong, Hui-Li; Yip, Desmond; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreGastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab, World Journal of Gastroenterology, vol.21, 17, 2015,pp 5352-5358
2013Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factorsClarke, Stephen; Pavlakis, Nick; Desai, Jayesh; Gibbs, Peter; Karapetis, Christos; Michael, Michael; Pricek, T.J.; Tabernero, Josep; Tebbutt, Niall C; Concord Clinical School: Medicine; Northern Clinical School: MedicineOverview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors, Critical Reviews in Oncology / Hematology (online), vol.85, 2, 2013,pp 121-135
2012Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world dataField, Kathryn; Ananda, Sumitra; Carter, Rob; Croxford, Matthew; Gibbs, Peter; Jones, Ian T.; Keating, Catherine; Kosmider, Suzanne; Tran, Ben; School of Public Health: NH&MRC Clinical Trials CentrePreliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data, Internal Medicine Journal, vol.42, 7, 2012,pp 794-800
2009Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 TrialSimes, Robert John; Tebbutt, Niall; Zalcberg, John; Au, Heather-Jane; Australasian Gastrointestinal Interest, Group; Colwell, Bruce; Evans, William K.; Findlay, Brian; Gibbs, Peter; Isogai, Pierre K.; Jonker, Derek J.; Karapetis, Christos; Links, Matthew; Mittman, Nicole; Moore, Malcolm; O'Callaghan, Chris; Siddiqui, Jehan; Tu, D.; Working Group on Economic Analysis of the National Cancer Institute of Canada, Clinical Trials Group; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreProspective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial, Journal of the National Cancer Institute, vol.101, 17, 2009,pp 1182-1192
2005A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.Smith, D; Yip, Desmond; Bailey, W.; Dowling, R.; Gibbs, Peter; Liechtenstein, M.; Lim, L.; Little, A.; Shapiro, Jeremy; Canberra Clinical School; MedicineA prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy., BMC Cancer, vol.5,(N/A),2005,pp 132-N/A